Results 61 to 70 of about 16,360 (195)
Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life [PDF]
OBJECTIVE: This study examined the effect of abatacept, a costimulation modulator, on the health-related quality of life (HRQOL) of patients with rheumatoid arthritis (RA).
Russell, Anthony S. +9 more
core
LRBA ve CTLA4 eksikliği olgularında abatacept molekülünün immünolojik etkileri
Giriş-Amaç: Lipopolysaccharide-responsive beige like anchor protein (LRBA) ve cytotoxic T lymphocyte antigen 4 (CTLA-4) eksiklikleri otoimmün bulgularla karşımıza çıkan primer immün yetmezlikler arasında yer alır.
BARIŞ, SAFA
core
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina +3 more
wiley +1 more source
Background To assess the risks of malignancies, infections and autoimmune diseases in patients with rheumatoid arthritis (RA) treated with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic
Gulsen Ozen +4 more
doaj +1 more source
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard +12 more
wiley +1 more source
Lisa M Lundquist1, Sabrina W Cole2, Jill M Augustine11Mercer University College of Pharmacy and Health Sciences, Atlanta, GA, 2Wingate University School of Pharmacy, Wingate, NC, USAAbstract: Rheumatoid arthritis is a chronic, progressive, autoimmune ...
Augustine JM, Cole SW, Lundquist LM
core
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients. [PDF]
BACKGROUND: CD28(neg) T cells, which display functional characteristic of oligoclonally expanded cytotoxic memory T lymphocytes, are believed to be pathologically relevant in rheumatoid arthritis manifestation.
Imberti, L +13 more
core +1 more source
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu +10 more
wiley +1 more source
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source

